Literature DB >> 20061604

The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules.

Mythili Yenjerla1, Nichole E LaPointe, Manu Lopus, Corey Cox, Mary Ann Jordan, Stuart C Feinstein, Leslie Wilson.   

Abstract

NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) is a neuroprotective peptide that shows cognitive protection in patients with amnestic mild cognitive impairment, a precursor to Alzheimer's disease. NAP exhibits potent neuroprotective properties in several in vivo and cellular models of neural injury. While NAP has been found in many studies to affect microtubule assembly and/or stability in neuronal and glial cells at fM concentrations, it has remained unclear whether NAP acts directly or indirectly on tubulin or microtubules. We analyzed the effects of NAP (1 fM-1 microM) on the assembly of reconstituted bovine brain microtubules in vitro and found that it did not significantly (p< 0.05) alter polymerization of either purified tubulin or of a mixture of tubulin and unfractionated microtubule-associated proteins. NAP also had no significant effect (p < 0.05) on the growing and shortening dynamics of steady-state microtubules at their plus ends, nor did it alter the polymerization or dynamics of microtubules assembled in the presence of 3-repeat or 4-repeat tau. Thus, the neuroprotective activity of NAP does not appear to involve a direct action on the polymerization or dynamics of purified tubulin or microtubules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061604      PMCID: PMC2844470          DOI: 10.3233/JAD-2010-1335

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  42 in total

1.  {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents.

Authors:  M L Michaelis; S Ansar; Y Chen; E R Reiff; K I Seyb; R H Himes; K L Audus; G I Georg
Journal:  J Pharmacol Exp Ther       Date:  2004-09-16       Impact factor: 4.030

2.  Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

Authors:  M Bassan; R Zamostiano; A Davidson; A Pinhasov; E Giladi; O Perl; H Bassan; C Blat; G Gibney; G Glazner; D E Brenneman; I Gozes
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

3.  Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.

Authors:  Virginia L Smith-Swintosky; Illana Gozes; Douglas E Brenneman; Michael R D'Andrea; Carlos R Plata-Salaman
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments.

Authors:  John Q Trojanowski; Amos B Smith; Donna Huryn; Virginia M-Y Lee
Journal:  Expert Opin Pharmacother       Date:  2005-05       Impact factor: 3.889

Review 5.  Microtubule treadmilling: what goes around comes around.

Authors:  R L Margolis; L Wilson
Journal:  Bioessays       Date:  1998-10       Impact factor: 4.345

6.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

7.  Substoichiometric binding of taxol suppresses microtubule dynamics.

Authors:  W B Derry; L Wilson; M A Jordan
Journal:  Biochemistry       Date:  1995-02-21       Impact factor: 3.162

8.  Dynamic instability of microtubule growth.

Authors:  T Mitchison; M Kirschner
Journal:  Nature       Date:  1984 Nov 15-21       Impact factor: 49.962

9.  The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Authors:  Illana Gozes; Inna Divinski
Journal:  J Alzheimers Dis       Date:  2004-12       Impact factor: 4.472

10.  The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.

Authors:  Illana Gozes; Roy Zaltzman; Janet Hauser; Douglas E Brenneman; Esther Shohami; Joanna M Hill
Journal:  Curr Alzheimer Res       Date:  2005-04       Impact factor: 3.498

View more
  14 in total

1.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

3.  A molecular and structural mechanism for G protein-mediated microtubule destabilization.

Authors:  Rahul H Davé; Witchuda Saengsawang; Manu Lopus; Sonya Davé; Leslie Wilson; Mark M Rasenick
Journal:  J Biol Chem       Date:  2010-11-26       Impact factor: 5.157

4.  Modeling the effects of drug binding on the dynamic instability of microtubules.

Authors:  Peter Hinow; Vahid Rezania; Manu Lopus; Mary Ann Jordan; Jack A Tuszyński
Journal:  Phys Biol       Date:  2011-08-12       Impact factor: 2.583

Review 5.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

6.  Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.

Authors:  Manu Lopus; Emin Oroudjev; Leslie Wilson; Sharon Wilhelm; Wayne Widdison; Ravi Chari; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

7.  ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Authors:  Y Ivashko-Pachima; C Laura Sayas; A Malishkevich; I Gozes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

8.  Notch signalling in adult neurons: a potential target for microtubule stabilization.

Authors:  Sara Anna Bonini; Giulia Ferrari-Toninelli; Mery Montinaro; Maurizio Memo
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

Review 9.  Therapeutic strategies for tau mediated neurodegeneration.

Authors:  Yasumasa Yoshiyama; Virginia M Y Lee; John Q Trojanowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-20       Impact factor: 10.154

10.  Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.

Authors:  Ming-Hui Yang; Shih-Cheng Chen; Yu-Fen Lin; Yi-Chia Lee; Ming-Yii Huang; Ko-Chin Chen; Hsin-Yi Wu; Po-Chiao Lin; Illana Gozes; Yu-Chang Tyan
Journal:  J Food Drug Anal       Date:  2019-01-12       Impact factor: 6.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.